<DOC>
	<DOC>NCT00234988</DOC>
	<brief_summary>The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.</brief_summary>
	<brief_title>A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Subject has nutritional obesity and BMI &gt;30 kg/m Type 1 or type 2 diabetes mellitus Inadequately controlled hypertension History of Gilles de la Tourette's Syndrome. Use of any MAOIs, SSRIs, amino acids, antimigraine drugs, opioids Hypothyroidism or hyperthyroidism. History of: benign prostatic hyperplasia neurological disorders psychiatric illness severe renal or hepatic impairments narrowangle glaucoma History of cardiovascular disease or cerebrovascular disease Persistent tachycardia at rest Pulmonary hypertension Phaeochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Sibutramine</keyword>
	<keyword>Obesity</keyword>
</DOC>